americanpharmaceuticalreviewJuly 28, 2021
Tag: 10X Genomics , Bio-Rad , PCR
10x Genomics Inc. announced that it has entered into a global settlement and cross-license agreement with Bio-Rad Laboratories Inc.. The agreement grants each company a non-exclusive, worldwide, royalty-bearing license to develop products and services related to single-cell analysis. The term of the agreement is for the life of the licensed patents. The cross license excludes products related to spatial analysis and In Situ analysis. It also excludes digital PCR products in the case of 10x Genomics. Both companies have agreed that each company’s patents are owned by each respective company.
“Today’s settlement underscores the value of our innovation and strong patent portfolios built over the last nine years,” said Eric Whitaker, General Counsel of 10x Genomics. "10x has invested nearly one billion dollars in research and development, which has led to more than 1,100 issued and pending patents and catalyzed a revolution in genomics around the world.”
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world, including in all of the top 100 global research institutions as ranked by Nature in 2020 based on publications and all of the top 20 global pharmaceutical companies by 2020 research and development spend, and have been cited in over 2,500 research papers on discoveries ranging from oncology to immunology and neuroscience.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: